24/7 Market News- Tempest Signs Agreement with Roche to Support Development of Amezalpat Combination Therapy
DENVER, Colo., Oct 10, 2024 (247marketnews.com)- Tempest Therapeutics (NASDAQ: TPST) introduced an agreement that calls for Roche to supply atezolizumab (Tecentriq) to advance the evaluation of amezalpat (TPST-1120) in a pivotal study led and sponsored by Tempest.
The move builds on the companies’ clinical collaboration, in which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study.
Stephen Brady, Tempest’s president and CEO, commented, “We’re excited to announce this agreement that supports the advancement of amezalpat into a pivotal study and reinforces both Tempest and Roche’s shared commitment to delivering groundbreaking cancer treatments for patients.
“Based on the positive Phase 2 data, I believe this combination therapy holds the potential to significantly improve first-line liver cancer treatment, and we look forward to amezalpat moving into this pivotal Phase 3 study.”
Tempest is preparing to start the Phase 3 study in the first quarter of 2025.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com